ePrints

A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis

Lookup NU author(s): Professor Alastair BurtORCiD

Downloads

• Published version [.pdf]

Abstract

Background Pathologists are often faced with the dilemma of whether to recommend continuation of methotrexate therapy for psoriasis within the context of an existing pro-fibrogenic risk factor, in this instance, patients with genetic hemochromatosis. Case presentations We describe our experience with two male psoriatic patients (A and B) on long term methotrexate therapy (cumulative dose A = 1.56 gms and B = 7.88 gms) with hetero- (A) and homozygous (B) genetic hemochromatosis. These patients liver function were monitored with routine biochemical profiling; apart from mild perivenular fibrosis in one patient (B), significant liver fibrosis was not identified in either patient with multiple interval percutaneous liver biopsies; in the latter instance this patient (B) had an additional risk factor of partiality to alcohol. Conclusion We conclude that methotrexate therapy is relatively safe in patients with genetic hemochromatosis, with no other risk factor, but caution that the risk of fibrosis be monitored, preferably by non-invasive techniques, or by liver biopsy.

Publication metadata

Author(s): Mathew J, Leong MY, Morley N, Burt AD

Publication type: Article

Publication status: Published

Journal: BMC Dermatology

Year: 2005

Volume: 5

Pages: 12

Date deposited: 01/01/1970

ISSN (electronic): 1471-5945

Publisher: BioMed Central Ltd.

URL: http://dx.doi.org/10.1186/1471-5945-5-12

DOI: 10.1186/1471-5945-5-12

Altmetrics

Share